New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 27, 2014
07:22 EDTLBIO, ARGS, AVXT, GALE, GNBTMaidstone Life Sciences to hold a conference
4th Annual Cancer Immunotherapy: A Long Awaited Reality Conference is being held in New York on March 27.
News For LBIO;ARGS;AVXT;GALE;GNBT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 22, 2014
14:08 EDTGALEGalena files to sell 2M shares of common stock for holders
Subscribe for More Information
10:02 EDTARGSArgos Therapeutics breaks ground on new 100K square foot facility
Subscribe for More Information
October 21, 2014
09:33 EDTGNBTGenerex Biotech announces publication of Ebola vaccine white paper
Generex Biotechnology announced that its wholly owned subsidiary, Antigen Express, issued a white paper outlining the advantages of its Ii-Key technology in the development of an effective Ebola vaccine. The Antigen Express vaccines can be generated quickly to meet the demands of new threats, with one of the most recent threats being the Ebola virus. The Antigen Express Ii-Key Hybrid technology specifically and efficiently activates CD4+ T cell responses and is capable of both stimulating efficient immune responses on its own as well as boosting the efficacy of other vaccines to generate more robust humoral and cellular immunity. Ii-Key Hybrids have been shown to be safe, well-tolerated, and to generate the desired specific immune response in humans in Phase I and II cancer vaccine trials as well as in a Phase I trial of Ii-Key hybrid vaccines targeted to the H5N1 and H1N1 influenza strains.
October 14, 2014
07:17 EDTGALEGalena receives notice of allowance of improvement patent for NeuVax in Japan
Galena Biopharma announced the notice of allowance from the Japanese Patent Office for NeuVax covering the use of NeuVax alone or in combination with other agents to prevent recurrence of any HER2/neu expressing breast cancer tumor having an immunohistochemistry level of 1+ or 2+, or a fluorescence in situ hybridization rating of less than about 2.0. NeuVax is a peptide immunotherapy for the prevention of cancer recurrence and is Galena's lead development agent in multiple ongoing and planned clinical trials. Once issued, the patent will expire in 2027, not including any patent term extensions.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use